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S_mmary Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of con-
tinuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was
administered according to a groupwise dose escalation schedule (group A, 3 x 104; group B, 3 x 105; group C,
3 x 106; group D, 6 x 106; group E, 18 x 106; and group F, 36 x 106 IU day-'). Each group consisted of at
least three patients. Intrapleural administration of IL-2 was associated with acceptable toxicity. All patients
were treated on an outpatient basis except for the patients at dose levels E and F. Dose-limiting toxicity was
observed at level F, 36 x 106 IU daily, and consisted of catheter infection, fever and flu-like symptoms.
Intrapleural IL-2 levels were high (>20 000 IU ml-') at levels E and F, while serum levels in most patients
were not or barely detectable (<3-30 IU ml-'). Intrapleural IL-2 levels were up to 6000-fold higher than
systemic levels. Intrapleural tumour necrosis factor alpha (TNF-a) levels varied greatly and did not correlate
with IL-2 dosage. Intrapleural mononuclear cells (MNCs) displayed IL-2-induced lymphokine-activated killer
(LAK) activity in all patients. Two patients were not evaluable for response owing to catheter-related
problems which precluded the delivery of IL-2. Partial response (PR) occurred in 4 of 21 evaluable patients
(19%; 95% confidence interval 5-42%) with a median time to progression of 12 months (range 5-37). Stable
disease (SD) occurred in seven patients with a median time to progression of 5 months (range 2-7). There
were no complete responses (CRs). The median overall survival was 15.6 months (range 3.0-43). No
relationship between the dose of IL-2 and response rate was observed. We conclude that IL-2 given
intrapleurally is accompanied with acceptable toxicity and has anti-tumour activity against mesothelioma. In
view of the refractory nature of the disease IL-2 may be a treatment option for mesothelioma. A formal phase
II study is warranted. Based on the observed toxicity, the lack of dose-response relationship and the
immunomodulatory effects seen at relatively low-dose IL-2, the recommended dose for a phase II study is
3 x I06IU day-' using the present treatment schedule.
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Untreated patients with pleural mesothelioma have a median
survival of 9 months and may survive just as long as treated
patients (Hillerdal, 1983; Law et al., 1984). Current treatment
methods do not appear to improve survival (Alberts et al.,
1988). Therefore, new treatment modalities should be inves-
tigated.
In intraperitoneal tumour models it has been demonstrated
that intracavitary administration of interleukin 2 (IL-2) can
induce very high numbers of lymphokine-activated killer cells
(LAKs) in the peritoneal exudate (Eggermont et al., 1988;
Eggermont 1989). Consequently, intrapleural administration
of IL-2 for the treatment of pleural mesothelioma appears to
be a reasonable therapeutic approach, particularly since
mesothelioma tends to be confined to the pleural cavity for
most of the course of the disease. Yasumoto et al. (1987)
reported the complete clearance of malignant cells after int-
rapleural instillations of IL-2 in patients with pleurisy due to
lung cancer. Astoul et al. (1993) reported objective responses
in mesothelioma patients treated with continuous intrapleural
IL-2 instillation.
Based on these observations, we performed phase I-II
study with intrapleural IL-2 in patients with pleural
mesothelioma stage I-IIA, classified according to the But-
chart staging system (Butchart et al., 1976).
Patients and methods
Patients
Staging and diagnosis of mesothelioma was based on com-
puterised tomographic (CT) scan of the chest, thoracoscopic
findings and histological examination of biopsy samples.
All biopsies were reviewed by our institution's pathologist.
The staining techniques used included haematoxylin and
eosin, special stains for reticulin and mucins (such as
mucicarmine, periodic acid-Schiff after diastase and the
alcian blue stain with and without prior digestion with
hyaluronidase) and the immunohistochemistry stain for
CEA, keratin, CAM-5.2 and an epithelial membrane antigen
MOC-31.
According to Butchart's staging system (Butchart et al.,
1976) stage I is defined as tumour confined within the capsule
of the parietal pleura, i.e. involving only ipsilateral pleura,
lung, diaphragm and external surface of the pericardium
within the pleural reflection. Stage IIA is defined as
mesothelioma invading chest wall or mediastinal tissues with
or without lymph node involvement ipsilaterally inside the
chest.
Eligibility criteria required histologically confirmed pleural
mesothelioma stage I-ILA, sufficient pleural effusion to insert
an intrapleural catheter, no signs of loculation on the CT
scan, no prior chemo-, radio- or immunotherapy, age <76
years, Karnofsy performance status > 80, no cardiovascular
disease, a white blood cell count > 4000 ml-', a platelet
count 100 000 ml-', haematocrit ) 30%, serum bilirubin
and creatinine levels within the institution's normal range, no
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active infection, no use of corticosteroids and obtained in-
formed consent.
Treatment
One to two weeks before the first administration of IL-2 a
Port-a-cath system was surgically inserted under general
anaesthesia. The correct intrapleural position of the catheter
was examined radiographically and a technetium-99m colloid
scan was made to evaluate the distribution of pleural fluid
throughout the pleural cavity.
Recombinant human IL-2 (Chiron, Amsterdam, The
Netherlands) was admi d as a continuous intrapleural
infusion at a dose according to a groupwise dose escalation
schedule (group A, 3 x 10'; group B, 3 x 105; group C,
3 x 10'; group D, 6 x 10'; group E, 18 x 10'; and group F,
36 x 10' IU day-') for 14 days, repeated every 4 weeks. After
two cycles, response to treatment was evaluated. Each group
consisted of at least three patients. Patients with stable
disease or response could receive up to a maximum of six
cycles. No intra-patient dose escalation was performed.
All patients were seen weekly at the outpatient clinic.
Masks and sterile gloves were used for all dressing changes
and dresing were changed only by trained nursing person-
nel.
Response and toxicity
Response was evaluated after every two treatment cycles
uing CT scan of the chest. Tumour response and toxicity
were assd according to the criteria of the World Health
Organization (1979). In case of measurable disease, complete
response (CR) was defined as the disappearance ofall known
disa for at eat 4 weeks; partial reponse (PR) as a
decrease >50% in tumour size for at kast 4 weeks; stable
diseas (SD) as a decrease of <50% in tumour size. Progres-
sive disease (PD) was defined as an increase >25% in the
diameter of any lesion or the appearance of a new lesion.
In case of unmeasurable but evaluable disease a CR was
defined as the complete disappearance of all known disease
for at least 4 weeks; a PR as an esimated decrease in tumour
size of > 50% for at least 4 weeks; SD as an estimated
decrease of less than 50% and lesions with estimated increase
of less than 25%. PD was defined as the appearance of any
new lesion not previously identified or estimated increase of
25% or more in existent lesions.
Pleural effusion was not considered an adequate parameter
of response or progression by itself. It would not detract
from a PR or SD. However, its continued presence would
reduce a CR to a PR.
Time to progression and survival was calculated from the
start of treatment to the date of progressive disease or death
restively, according to the Kaplan and Meier (1958)
method.
Toxicity was recorded and analysed using the WHO
grading system. For toxiities not induded in the WHO
guidelines, a grading system was used ranging from mild
(grade 1) to life-threatening (grade 4).
Immnonitoring
All samples were taken at the same time ofday (preferably in
the morning) since a drcadian rhythm has been described for
a number of functions. Mononuclear lls (MNCs), senum
samples and pleural fluid (if present) were colle weekly
during each course and cryopreserved until tested.
Immunophenotyping
MNCs were isolated from heparinised pleural and peripheral
blood samples by density centrifation (Ficoll-lpaque).
MNCs were washed, resuspended at a concentration of
1 x 106 ml-' in phosphate-buffered saline (PBS) + 1% bovine
serum albumin (BSA) and stained with fluorescein
isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated
monoclonal antibodies (MAbs).
The following MAbs were used: anti-Leu4/F1TC (CD3);
anti-Leu3a/FITC (CD4); anti-Leu2a/PE (CD8); anti-Leu 1Ic/
PE (CD16); anti-Leul2/FTC (CD19) and anti-Leul9/PE
(CD56). All MAbs were purchased from Becton and Dickin-
son, (San Jose, CA, USA).
After incubation with the MAb for 30min at OC, MNCs
were fixed in PBS containing 1% paraformaliehyde, stored
at 4-C and flow cytometry was performed within 24 h using a
FACScan (Becton and Dickinson).
Cytotoxicity assays
Cytotoxic activity of MNCs was determined in a standard
3 h chromium-51 release assay. Briefly, lymphocytes were
seeded in triplicate in 96-well, round-bottomed microtitre
plates. Target cells labelled with chromium-51 were added
and at the end of the incubation period (37-C and 5%
carbon dioxide), supernatants were collected, and chromium-
51 release was measured. Target cells were the NK-sensitive
K562 chronc myelogenous leukaemia cell line and the NK-
resistant, LAK-sensitive Daudi Burkitt lymphoma cell line.
Determination ofcytokine levels
In patients from whom pleural fluid could easily be obtained,
this was done before and during treatment with IL-2. At the
same time blood samples were taken in order to compare
intrapleural IL-2 and tumour necrosis factor alpha (TNF-a)
levels with simultaneous blood IL-2 and TNF-a levels.
IL-2 was measured with a double antibody radio-
immunoassay using a polyclonal antiserum (IRE-Medgenix,
Fleurus, Belgium). The detection limit is about 0.5 U ml-'
(3.0 IU ml-'). The interassay coefficient ofvariation at a level
of 10 U ml-' is 6.8%. One unit in this assay corresponds
with 6 IU.
TNF-a was measured with a coated tube
immunoradiometric assay (IRE-Medgenix, Fleurus, Bel-
gium). The detection limit is 5 ng l-' and the interassay
coefficient of variation at a level of 131 ngl-' is 7.2%.
ResdA
Toxicityprofile and twnour response
Twenty-three male patients with epithelial type malignant
pleural mesothelioma stage I or HA, without prior treatment,
were eligible for the study. Most of them were shipyard
workers with a history of asbestos exposure. Their median
age was 57 (range 47-71) and their median Kanofsky per-
formance status 100 (range 90-100).
Twenty-one patients were evaluable for toxcity and
tumour response (Tables I and H). Two patients were
inevaluable for toxicity and response owing to catheter-
related problems which prevented the delivery of any IL-2.
At least one treatment cycle of 14 days was recived by five
patients at 3 x 104IU day-', two patients at 3 x 105 IU
day-, three patients at 3 x I0'IU day-', three patients at
6 x10 IUday-', three patients at 18 x 10' IU day-' and
one patient at 36 x 10 IU day-'. Five patients were starte
at the highest dose level but only one patient was able to
receive one cycle. The other four patients were unable to
complete one treatment cycle because of catheter-related
infections which required catheter removal before the com-
pletion of the first cycle. After five patient entries at this dose
level the study was stopped. Hence, this dose was not
tolerated by four of the five patients (Table 1).
In general IL-2-mediated toxicity was mild to moderate,
except at the highest dose level. At this level, in addition to
the catheter-related infections, fever and flu-hlke symptoms
were dose lmiting. The systemic side-effects such as fever and
skin toxicity corresponded with serum IL-2 levels, which
reached 301Uml-' in group F. All patients rLived theirhwapmwm L-2 in -mesudlsum
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Table I Toxicity in relation to intrapleural IL-2 in 21 evaluable patients (WHO grade > 2)
Dose level (IU)
3 x 10 3 x101 3 x 06 6 xJO' 18 x 106 36 x 106
Group A B C D E F
Patients 5 2 3 3 3 5
No. of cycles 14 8 11 10 7 4
Fever >38 C - 1' 1 1 2 5
Flu-like - 1 1 - - 4
Myalgia - I - 1 - 2
Arthralgia - 1 - -
Diarrhoea - - - - -I
Non-productive cough 1 1 2 1 1 1
Dyspnoea 1 - 1 2 2 -
Arrhythmia - - - 1 - -
Anorexia - - - 1 1 1
Skin - - - - - 3
Creatinine elevation - - - - - 1
Leucocytosis (>I0000 cells ml') 1 1 1 3 3 3
Eosinophilia (>2000 cellsml') - 1 2 2 1 1
Infection - 1 1 - 1 4
Bacterial culture S. aureus S. aureus Streptococcus S. epidermidis (3)
Eubcterinm (1)
Thoracotomy due to empyema - 1 2 - 1 1
aNumber of patients per dose level experiencing toxicity.
Table H Clinical data and response to therapy in 21 evaluable patients with pleural mesothelioma
treated with intrapleural IL-2
Progression-free Overall
Patient IL-2 No. of survival survival
nwnber (IU day-') Age cycles Response (months) (months)
1 3x1I4 51 4 PR 5 15
2 3 x10 47 1 SD 4 8
3 3 x I0 50 0 NE' - 7.5
4 3 x104 63 5 SD 5 9
5 3 x10 71 2 PD 1 5
6 3 x I0 57 2 PD 1 19
7 3 x10 49 0 NE! - 10
8 3 x I0 54 6 PR 17 23
9 3 x I0 52 2 PD 1 10
10 3 x 10' 59 1 PR 12 31
11 3 x10 62 4 SD 3 6
12 3x106 51 6 PR 37 43
13 6 x 106 63 6 SD 5,5 28
14 6x10 64 2 PD 1 16
15 6x10' 62 2 PD 1 17
16 18 x 106 69 2 SD 7 10
17 18 x 10' 62 3 SD 2 18
18 18 x 106 59 2 PD 2 3
19 36x 106 48 2 xI SD 6 10
20 36x106 49 1 SD _b 9
21 36x106 55 1 SD 5 26
22 36x106 54 1 SD _b 16
23 36 x 10' 59 3/4 SD _b 26+
'Patients 3 and 7 did not receive IL-2 intrapleurally owing to catheter-relatedproblems and were thus
inevaluable. bPatients 20, 22 and 23 received additional cisplatin and etoposide, thus appropriate
progression-free survival cannot be determined.
treatment in an outpatient setting except for the last five
patients who were treated at level F, 36 x 106 IU day-'. No
serious systemic adverse effects such as hypotension, car-
diovascular disturbances, pulmonary oedema, liver and renal
dysfunction were observed, with the exception of one patient
in group F, in whom grade 3 nephrotoxicity was noted. Mild
leucocytosis (10 000-12 000 cellsml-') and eosinophilia
(2000-3500 cells ml-') in the peripheral blood were seen in
most patients at all dose levels.
Treatment-related complications were infection ofthe Port-
a-cath systems in seven patients, four of whom were treated
at the highest dose level in group F.
Clinical signs of empyema were noted in five of the seven
patients with a Port-a-cath infection. These five required
removal of the Port-a-cath system in combination with
drainage by thoracotomy. As can be seen in Table I a variety
of micro-organisms were cultured from pleural samples and
removed Port-a-cath systems of these patients which suggests
a secondary bacterial infection in necrotic tissue.
Patients received from less than one up to six complete
treatment cycles. There were no complete responses. Partial
response occurred in 4 of 21 evaluable patients (19%; 95%
confidence intervals 5-42%) with a median time to progres-
sion of 12 months (range 5-37). Stable disease occurred in
seven patients, the median time to progression was 5 months
(range 2-7). Six patients had progressive disease. The
median overall survival was 15.6 months (range 3.0-43).
Responses occurred at different dose levels, therefore noSHGoeyeti
dose-response relationship can be establshed (Table H).
Figure 1 shows a representative example of a tumour res-
ponse.
Tree of the four PRs was a long-lasting response under-
went thoracotomy. In patients 10 and 8, an infected Port-a-
cath with concomitant empyema was noted after one and
four cycles, respectively (Table II). In both these patients
massive tumour necrosis was found. Bacterial cultures
revealed Staphylococcus aureus in both cases. In patient 8,
whose near-complete response lasted 17 months, a fenestra-
tion of the thoracic wall had to be performed in order to
prevent recurrent empyema. In a second stage, the pleural
cavity, which was macroscopially still free of tumour, was
closed by a pedicled omentoplasty. The patient did very well
for 17 months, until mesothelioma developed in the cont-
ralateral pleural cavity. In patient 12, a fistula developed
after five cycles and required ribresection. Thoracotomy
showed a completely necrotised pleural mesothelioma.
Bacterial cultures were negative. One of the multiple pleural
biopsies contained mesothelioma cells. Two patients with SD,
patients 19 and 16, showed clinical signs of empyema after
one and two cycles respectively. A thoracotomy was per-
formed and extensive necrosis was found in the remaining
tumour. Bacterial culture reveald Streptococcus in one and
was negative in the other patient. In thew three patients (12,
16 and 19) CT scans showed no tumour rgression whereas
histological examination revealed extensive tumour necross.
These findings underscore the difficulties in the clinical
evaluation of response in mesothelioma.
Immwwmonitoring
After intrapleural administration of IL-2 a mild increase of
CD3-56+, CD3+56+ and CD3-16+ lymphocytes was
observed in pleural effusion as well as in peripheral blood.
All other T-lymphocyte subsets remained at normal levels.
At dose levels A-D cytotoxiity assays showed a
significant induction of LAK activity by pleural effusion-
derived MNCs but not by peripheral blood MNCs. At dose
levels E and F, LAK activity was induced in MNCs from
both sites. Of note, no differences in LAK activity werseen
between responders and non-responders.
Determination ofcytokine levels
Intrapleural as well as serum IL-2 levels were determined.
Intrapleural levels were very high and correlated with the
administered dose of IL-2. Intrapleural levels varied from
6-llOIUml-' in group A to as high as 66000-1920001U
ml-' in group F. Serum IL-2 levels became measurable only
in groups E and F and varied in the eight patients treated at
those levels from <3 IUml' to 30 IUml '. Itraplural
LL-2 levels were <6000 times higher than serum lves.
-Intrapleural TNF-1 levels varied from 50-125pgmlI in
group A to 235-405 pgml-' in group F. However, no cear
relationship between TNF-c and IL-2 lewls was observed as
TNF-a levels in groups B-E varied from 292-1141 pgml-'.
In this phase I-II study on the toxicity and efficacy of
intrapeural administraton of IL-2 in patients with pleural
mesothelioma we observed anti-tumour activity with accep-
table toxcity. The response rate of 19% in 21 patients is of
interest as mesothelioma is known to be refractory to treat-
ment.
The basis of this study was the observation of a
dose-response relationship in experimental tumour models
(Etfinghausen et al., 1986; Rosenberg et al., 1987, 1989;
Fermont et al., 1988). Systemic high-dose EL-2 therapy is
associted with severe toxicity, which may prohibit appla-
tion of doses with optimal anti-tumour effects (Herberman,
1989). Intrapleural aministration of EL-2 is therefore a
logical approach as it can be expected that very high local
a
b
Fugw 1 Partial reponse of plural mesodioma (evahlable
disease and a mediasinal lymph node (measurable diseas)
metastasis in the left hemithorax. (a) Preteaen C scan. (b)
After wo cydes of IL-2.
levels of IL-2 can be delivered without severe systemic
adverse effects. We have demonstrated that high intrapleural
levels of IL-2 are associated with mild to moderate toxicity,
except in those patints treated at the highest dose level F
with 36xl0'IUday '. All patients in groups A-E were
treated on an outpatient basis.I1bapir L-2 in m xsatHoNa
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Intrapleural administration of various biological response
modlifiers may have significant anti-tumour effects against
intrapleural malignant disease. Uchida et al. (1984) reported
that intrapleural instillation with the biological response
modifier OK-432 significantly increased autologous tumour
killing by tumour-associated large granular lymphocytes. The
intrapleural instillation of natural a-interferon was reported
to be effective against malignant pleural effusions by Rosso et
al. (1988). Recently, Markowitz et al. (1992) reported on the
efficacy of intracavity administration of a-interferon. Boutin
et al. (1991) reported four CRs and two PRs after weekly
intrapleural administration of y-interferon in 22 patients with
mesothelioma, also underlining the therapeutic potential of
locoregional cytokine therapy.
Anti-tumour effects after intrapleural administration of
TNF--a have been reported by Karck et al. (1990). Int-
rapleural administration <200fg m-2 weekly in seven
patients with malignant pleural effusion led to complete
disappearance of tumour in three patients without side-
effects. The same group reported that in patients with
ovarian cancer and recurrent ascites intraperitoneal administ-
ration of TNF-c resulted in the disappearance of ascites in
seven of nine patients.
Yasumoto et al. (1987) demonstrated that low intrapleural
doses of IL-2 were sufficient to induce LAK activity in the
pleural exudate and to reduce malignant pleural effusions.
Manning et al. (1989) have shown that these activated lym-
phocytes were able to kill NK cell-resistant human
mesothelioma cells.
Astoul et al. (1993) reported a relatively high response rate
(71/15 patients) in mesothelioma patients who were treated
with intrapleural IL-2 in a dose escalation study. The
preponderance of responses was observed in stage I disease.
We made similar observations in our study. Significant
LAK activity was displayed by MNCs collected from the
pleural effusions after intrapleural administration of IL-2. No
LAK activity was displayed by the peripheral MNCs, except
at the highest two dose levels in groups E and F. However,
LAK activity and response did not correspond with IL-2
dose level, intrapleural IL-2 level or intrapleural TNF-a level.
Immunophenotyping of intrapleural and peripheral MNCs
showed some changes after intrapleural administration of
IL-2. In this study, the dose of IL-2 did not correlate with
response and none of the parameters investigated by
immunophenotyping, cytotoxicity assays and determination
of cytokine levels corresponded with the outcome of treat-
ment.
Dosages of IL-2 in this study were tolerable up to and
including level E, 18 x 106IU day-'. However, at level F,
36 x 106IU day-', catheter-related infection was the most
pronounced and dose-limiting side-effect. Others have
reported neutrophil dysfunction during IL-2 administration,
including decreased chemotaxis and Fc receptor expression
(Murphy et al., 1988; Jablons et al., 1990; Klempner et al.,
1990). High-dose IL-2 increased the risk of bacteraemia
significantly, which led to a reduction of catheter indwelling
time (Richards et al., 1991). These facts may explain the high
incidence ofcatheter-related infections in our patients, partic-
ularly in group F, and after repeated administration of IL-2
at the lower doses.
It remains uncertain if and to what extent these infections
have played a role in the induction of an anti-tumour res-
ponse, as three of the four responders developed an
empyema, but two of the five patients with an empyema had
no response. In addition, IL-2 by itself induced high int-
rapleural levels of TNF-a in the majority of the patients
treated.
We conclude that intrapleural administration of cytokines
should be explored further as a new mode of treatment for
pleural mesothelioma. IL-2 given intrapleurally appears to
have anti-tumour activity against mesothelioma. We are
aware of the difficulty in recommending a daily dose of IL-2
because of the small numbers of patients in each group and
the frequent occurrence of empyema, but given the facts that
(1) no correlation was found by us and by others between
IL-2 dose and anti-tumour response, (2) low intrapleural IL-2
doses are sufficient to induce LAK activity by MNCs which
can kill NK cell-resistant human mesothelioma cells and (3)
mild toxicity was seen below 6 x 106 IU of IL-2 we suggest a
daily dose of 3 x 106 IU of IL-2 for a phase II study.
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